Cramer’s Mad Dash: Eli Lilly
Speakers
Jim Cramer -- Host of Mad Dash
— CNBC host, Mad Money
Summary
- Eli Lilly acquired Sinteza for $7.8 billion, focusing on a peptide for brain disorders beyond sleep issues.
- The deal underscores Lilly's strategy to tackle historically difficult brain diseases like Parkinson's and ADHD.
- Lilly's tie-up with NVIDIA aims to accelerate drug discovery by processing peptides through large databases in days instead of years.
- Lilly generates significant free cash flow, which it deploys aggressively for acquisitions to fuel future therapies.
- Many of Lilly's commercial drugs originate from acquisitions made prior to their commercial viability.
- The acquired peptide has potential applications in wakefulness, narcolepsy, and other brain conditions, indicating broader utility.
- Lilly is portrayed as risk-tolerant and forward-thinking under CEO David Ricks, willing to invest in areas where others have failed.
- Technology partnerships, such as with NVIDIA, are central to Lilly's efficiency in drug development and innovation.
Trade Ideas
Jim Cramer explicitly stated that Eli Lilly acquired Sinteza for $7.8 billion for a peptide impacting the brain for various disorders, and they are taking on hard brain issues like Parkinson's and ADHD, showing a willingness to lose money and go big. This acquisition demonstrates Lilly's risk-tolerant strategy to invest in challenging disease areas, complemented by their tie-up with NVIDIA to speed up drug discovery through advanced data processing, potentially leading to breakthrough therapies. Direction is LONG because Lilly's forward-thinking approach, strong cash flow for M&A, and technological efficiencies position it for long-term growth in lucrative and underserved medical markets. The main risk is the failure of acquired assets or drug candidates in development, given the high historical failure rates in brain disease treatments and the inherent uncertainties in biotech R&D.
Up Next
This CNBC video, published April 01, 2026, features Jim Cramer discussing LLY. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: Jim Cramer · Tickers: LLY